Immunotherapy in Patients with Systemic MycosesA Promising Adjunct
作者:
Evangelia Farmaki,
Emmanuel Roilides,
期刊:
BioDrugs
(ADIS Available online 2001)
卷期:
Volume 15,
issue 4
页码: 207-214
ISSN:1173-8804
年代: 2001
出版商: ADIS
关键词: Cytokines, therapeutic use;Granulocyte colony stimulating factors, therapeutic use;Granulocyte macrophage colony stimulating factors, therapeutic use;Immunotherapies, therapeutic use;Interferon gamma, therapeutic use;Mycoses, treatment
数据来源: ADIS
摘要:
Evidence from severalin vitroand animal model studies suggests a modulatory role of haemopoietic, TH1 and TH2 cytokines in host defence against fungi, and highlights their potential utility as adjunctive therapy for management of systemic mycoses (SM). However, there are limited clinical data to support the use of cytokines in prevention and treatment of SM. Thus, at present no adjunctive treatment is justified for routine use in all patients. Potential application of these immunomodulatory agents include the use of granulocyte-macrophage colony-stimulating factor or macrophage colony-stimulating factor in the management of mycoses in neutropenic patients with myelogenous leukaemia or bone marrow transplantation. Interferon-γ may have a useful role against aspergillosis in patients with chronic granulomatous disease. Granulocyte colony-stimulating factor-elicited white blood cell transfusions may be life saving to patients with refractory SM. Better understanding of synergy between cytokines and specific antifungals may provide powerful tools for managing these serious infections.
点击下载:
PDF
(116KB)
返 回